Janux Therapeutics (NASDAQ:JANX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a report published on Monday morning,Benzinga reports. The firm currently has a $70.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on JANX. Leerink Partners upped their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Wedbush restated an “outperform” rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $88.00.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $31.83 on Monday. The firm has a market capitalization of $1.67 billion, a P/E ratio of -27.20 and a beta of 3.16. The company has a 50-day simple moving average of $43.25 and a 200-day simple moving average of $47.86. Janux Therapeutics has a one year low of $31.36 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Activity at Janux Therapeutics

In related news, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,668 shares of company stock worth $2,577,515. 29.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares during the period. Lester Murray Antman dba SimplyRich lifted its holdings in shares of Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock valued at $1,301,000 after acquiring an additional 16,351 shares during the period. Algert Global LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at $1,112,000. Ally Bridge Group NY LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at $4,943,000. Finally, FMR LLC lifted its holdings in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after acquiring an additional 47,075 shares during the period. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.